Atlas Trials

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

Clinical trial NCT07053059 · RECRUITING

Trial details

NCT number
NCT07053059
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Lymphocytic Leukemia (ALL)
Start date
2025-08-26
Primary completion
2028-05-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.